Maximum bite force in patients with spinal muscular atrophy during the first year of nusinersen therapy – A pilot study

OBJECTIVES: Spinal muscular atrophy is a monogenic disease characterized by progressive spinal and bulbar muscle weakness and atrophy. It is caused by the degeneration of alpha-motoneurons. The recent approval of the antisense oligonucleotide nusinersen highlights the need for reliable clinical tool...

Descripción completa

Detalles Bibliográficos
Autores principales: Kruse, Teresa, Heller, Raoul, Wirth, Brunhilde, Glöggler, Julia, Wurster, Claudia D., Ludolph, Albert C., Braumann, Bert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pacini Editore Srl 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460731/
https://www.ncbi.nlm.nih.gov/pubmed/32904902
http://dx.doi.org/10.36185/2532-1900-010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460731/
https://www.ncbi.nlm.nih.gov/pubmed/32904902
http://dx.doi.org/10.36185/2532-1900-010

Ejemplares similares